Morgan Stanley
TLX

Morgan Stanley’s Telix Pharmaceuticals TLX Stock Holding History

Morgan Stanley’s Portfolio TLX Stock Details TLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.91M Buy
165,978
+49,538
+43% +$504K ﹤0.01% 4872
2026
Q1 		$1.11M Buy
116,440
+98,787
+560% +$753K ﹤0.01% 5080
2025
Q4 		$132K Buy
17,653
+14,419
+446% +$139K ﹤0.01% 6085
2025
Q3 		$30.9K Sell
3,234
-1,168
-27% -$14.3K ﹤0.01% 6557
2025
Q2 		$70.7K Sell
4,402
-1,232
-22% -$20.7K ﹤0.01% 6245
2025
Q1 		$94.4K Buy
+5,634
New +$98.4K ﹤0.01% 6038

Other funds holding TLX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Lazard Asset Management
Lazard Asset Management New York $66.1B AUM 33.53% 1-Year Est. Return
PIC
Portland Investment Counsel Burlington, Ontario, Canada $358M AUM 26.37% 1-Year Est. Return
PAG
Private Advisor Group Morristown, New Jersey $21.8B AUM 28.57% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
IWC
Integrated Wealth Concepts Waltham, Massachusetts $20.5B AUM 24.45% 1-Year Est. Return
HWAM
Hennion & Walsh Asset Management Parsippany, New Jersey $3.5B AUM 41.95% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
William Blair & Company
William Blair & Company Chicago, Illinois $38.4B AUM 25.71% 1-Year Est. Return
RBI
Raiffeisen Bank International Vienna, Austria $8.53B AUM 46.94% 1-Year Est. Return

Morgan Stanley's TLX Position: Q2 2026 in Review

Morgan Stanley increased its Telix Pharmaceuticals (TLX) stake by 43% in Q2 2026, buying an estimated $504K and bringing the position to 165,978 shares worth $1.91M. The position accounts for ﹤0.01% of the portfolio, ranked #4872.

Morgan Stanley first reported a position in TLX in Q1 2025 and has held it in 6 quarters since. 61 funds tracked by Wall St. Rank hold TLX as of Q2 2026.

  • Morgan Stanley held 165,978 shares of Telix Pharmaceuticals worth $1.91M as of Q2 2026.
  • Morgan Stanley bought 49,538 Telix Pharmaceuticals shares in Q2 2026, an estimated $504K.
  • Telix Pharmaceuticals made up ﹤0.01% of Morgan Stanley's portfolio in Q2 2026, its #4872 holding.
  • Morgan Stanley first reported a position in Telix Pharmaceuticals in Q1 2025 and has held it in 6 quarters since.
  • 61 funds tracked by Wall St. Rank held Telix Pharmaceuticals as of Q2 2026.

Based on Morgan Stanley's 13F filing for Q2 2026, filed 13 Aug 2026.